|
gptkbp:instanceOf
|
gptkb:drug
muscle relaxant
|
|
gptkbp:ATCCode
|
gptkb:M03BA02
|
|
gptkbp:brand
|
gptkb:Soma
gptkb:Carisoma
Vanadom
|
|
gptkbp:CASNumber
|
78-44-4
|
|
gptkbp:compatibleWith
|
gptkb:European_Union
|
|
gptkbp:contraindication
|
porphyria
|
|
gptkbp:countryOfOperation
|
gptkb:India
gptkb:United_States
|
|
gptkbp:discoveredBy
|
gptkb:Wallace_Laboratories
|
|
gptkbp:drugClass
|
carbamate
|
|
gptkbp:eliminationHalfLife
|
2 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C12H24N2O4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
carisoprodol
|
|
gptkbp:introducedIn
|
1959
|
|
gptkbp:legalStatus
|
gptkb:Schedule_IV_controlled_substance_(US)
prescription only
|
|
gptkbp:mechanismOfAction
|
central nervous system depressant
|
|
gptkbp:metabolism
|
liver
meprobamate
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribedWith
|
gptkb:codeine
gptkb:aspirin
|
|
gptkbp:riskFactor
|
abuse potential
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
headache
drowsiness
dependence
|
|
gptkbp:usedFor
|
muscle pain
musculoskeletal conditions
|
|
gptkbp:bfsParent
|
gptkb:Muscle_Relaxants,_Central
gptkb:Schedule_IV_controlled_substance_(US)
|
|
gptkbp:bfsLayer
|
7
|